2-TUR QANDLI DIABETI MAVJUD BEMORLARDA SURUNKALI BUYRAKLAR KASALLIGINING KECHISHIGA SGLT2 INGIBITORLARIDAN EMPAGLIFLOZINLAR, DAPAGLIFLOZINLAR VA KANAGLIFLOZINLAR TA'SIRINING TAQQOSLAMA TAHLILINI O’RGANISH.

Authors

  • Abdiqodirova D.A. Author

Keywords:

2-tur qandli diabet, surunkali buyrak kasalligi, SGLT2-ingibitorlari, empagliflozin, dapagliflozin, albuminuriya

Abstract

 Ushbu tadqiqot 2-tur qandli diabet (QD) bilan og‘rigan bemorlarda surunkali buyrak kasalligi (SBK) kechishiga SGLT2-ingibitorlari 
(empagliflozin, dapagliflozin, kanagliflozin) ning ta’sirini o‘rganish va ularning samaradorligini taqqoslashga qaratilgan.

References

1. American Diabetes Association (ADA). (2023). Diabetes Care Guidelines.

2. Heerspink, H. J., et al. (2020). SGLT2 inhibitors and kidney protection: A meta

analysis. Lancet, 395(10224), 753-762.

3. Perkovic, V., et al. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes

and CKD. NEJM, 380(24), 2295-2306.

4. Bakris, G. L., Agarwal, R., Anker, S. D., et al. (2021). Empagliflozin SBK va yurak

yetishmovchiligida: EMPA-KIDNEY tadqiqoti natijalari. The Lancet Diabetes &

Endocrinology, 9(7), 461-474.

5. Zinman, B., Wanner, C., Lachin, J. M., et al. (2022). SGLT2-ingibitorlarining yurak

qon tomir va buyrak funktsiyasiga ta’siri: Klinik tadqiqotlar sharhi. Diabetes Care,

45(3), 529-541.

Published

2025-03-26

How to Cite

2-TUR QANDLI DIABETI MAVJUD BEMORLARDA SURUNKALI BUYRAKLAR KASALLIGINING KECHISHIGA SGLT2 INGIBITORLARIDAN EMPAGLIFLOZINLAR, DAPAGLIFLOZINLAR VA KANAGLIFLOZINLAR TA’SIRINING TAQQOSLAMA TAHLILINI O’RGANISH. (2025). Global Science Review, 2(1), 423-430. https://global-science-review.com/ojs/index.php/gsr/article/view/239